SCARA3 and prostate cancer: It has been reported that miR-650 works as an oncomirna in hepatocellular carcinoma, colorectal cancer, prostate cancer, and gastric cancer, targeting ING4, NDRG2, and SCARA3 (also known as CSR1) TSG [13,14,15,16].